

FINAL EXAM
JUNE 2018

NATIONAL BOARD OF EXAMINATIONS

NEPHROLOGY

PAPER-I

NEPHRO/J/18/20/I

Time: 3 hours

Max. Marks:100

Important Instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. a) Approach to a patient with hypercalcemia 6+4
b) Management of hypercalcemia
2. a) Anatomy of renal vasculature. 5+5
b) Role of Renin-Angiotensin system in control of GFR.
3. Human Leucocyte Antigen (HLA): 4+2+4
a) Class I and Class II HLA antigen molecules.
b) Enumerate the non-HLA antigens of significance in renal transplantation.
c) Three-signal model of T Cell Activation.
4. Meta-analysis: 2+3+5
a) Definition
b) Advantages and problems
c) Steps in a Meta-analysis
5. Refractory hypertension: 3+4+3
a) Define and discuss the etiology
b) Management
c) Renal denervation in treatment of refractory hypertension
6. a) Structure and functions of Glomerular basement membrane. 4+4+2
b) Structure and functions of Podocyte.
c) Enumerate the Podocytopathies.
7. a) Etiological classification of Polyuria. 4+4+2
b) Approach to a patient with polyuria.
c) Enumerate the therapies for treatment of Diabetes Insipidus.
8. Renal fibrosis: 4+4+2
a) Mechanisms of renal fibrosis
b) Role of TGF- Beta /SMAD signaling
c) Treatment targets in renal fibrosis

P.T.O.

FINAL EXAM
JUNE 2018

NATIONAL BOARD OF EXAMINATIONS

9. Urinalysis: 5+5
a) Target parameters in urinalysis
b) Various types of crystals in health and disease
10. Type 2 diabetic nephropathy - Diabetic Kidney Disease (DKD): 8+2
a) Various clinical trials in prevention of progression of DKD.
b) Discuss novel therapeutic perspectives in DKD.

www.FirstRanker.com